Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-02-2011 | Invited Commentary

Genomics, histopathology, and the tumor microenvironment: new relationship or old friends re-discovered?

Author: Daniel W. Visscher

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Excerpt

Efforts to improve recurrence risk stratification for breast cancer patients have increasingly focused on rapidly developing gene expression profiling and informatics technologies. Already, these powerful innovations have advanced and “personalized” evaluation of tumors to a degree not seen since application of histopathology. Genomic assays have also stimulated new and valuable insights into classical pathological features. For example, many of the genes that comprise well-studied expression profiles or prognostic assays, such as intrinsic subtype or OncotypeDXTM, either mediate, control, or measure tumor cell proliferation. It is therefore no surprise that these profiles are highly correlated with pathologic tumor grade, particularly mitotic index [1]. …
Literature
1.
Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R (2008) Histopathologic variables predict OncotypeDXTM Recurrence Score. Mod Pathol 21:1255–1261CrossRefPubMed
2.
West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M (2005) Determination of stromal signatures in breast carcinoma. PLoS Biol 3(6):1101–1110CrossRef
3.
Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB (2008) The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest 88(6):591–601CrossRefPubMed
4.
de Kruijf EM, van Nes JG, can de Velde CJ, Putter H, Smit VT, Liefers GJ, Kupppen PJ, Tollenaar RA, Mesker WE (2010) Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Can Res Treat. Apr 2 [epub ahead of print]
5.
Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA (2007) The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 29(5):387–398PubMed
6.
Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA, Tanke HJ (2009) Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol 31(3):169–178PubMed
7.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158–5165CrossRefPubMed
8.
Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project protocol no. 4. Cancer 36:1–85CrossRefPubMed
Metadata
Title
Genomics, histopathology, and the tumor microenvironment: new relationship or old friends re-discovered?
Author
Daniel W. Visscher
Publication date
01-02-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0930-z

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Epidemiology

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study

Clinical trial

Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study

Clinical trial

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern

Preclinical study

Mutations and polymorphic BRCA variants transmission in breast cancer familial members

Preclinical Study

Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients

Preclinical study

Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits